Dr. Vinod Jaskula-Ranga
Chief Executive Officer
Dr. Vinod Jaskula-Ranga is the Chief Executive Officer of Hunterian Medicine, a pre-clinical biotechnology company focused on CRISPR gene-editing technologies. He is the lead inventor on 3 issued or allowed U.S. patents for his groundbreaking CRISPR and AAV therapeutic-delivery technology, and over 75 U.S. and international patents pending. Dr. Jaskula-Ranga’s research has been highlighted by Chemical & Engineering News, Genetic Engineering & Biotechnology News, Biotechniques, Xconomy, and GenomeWeb, among others. Prior to founding Hunterian Medicine, he completed a fellowship in Genetic Engineering and Molecular Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine, where he received his Ph.D. in Molecular Biology and Genetics and trained in the laboratory of Nobel Laureate Dr. Carol Greider. Dr. Jaskula-Ranga also holds a B.A. in Religion from Case Western Reserve University, where he was awarded the Ratner Family Prize in recognition of the “Highest Academic Achievement.”
Chief Business Officer
Christian Johansson is Chief Business Officer of Hunterian Medicine. Christian was Maryland’s Secretary of Business and Economic Development (Commerce Secretary) where he helped shape policies leading to record investment in the life sciences, university research and venture capital investments, earning Maryland the U.S. Chamber of Commerce’s No. 1 ranking in innovation and entrepreneurship. He has previously held roles as President, Chairman, and CEO in public and privately owned companies. Christian also founded an international medical assessment and consulting company, and a venture-backed software company. He currently serves on multiple boards, including the Johns Hopkins School of Nursing Advisory Board. Christian received his B.A. in Biology from Brown University, where he co-authored a paper in Nucleic Acids Research. After initially entering medical school, Christian earned his MBA from Harvard Business School.
Robert C. Lorette
Chief Licensing Officer & Head of Business Development
Robert C. Lorette serves as Chief Licensing Officer and Head of Business Development of Hunterian Medicine. Bob is also President and CEO of Boston Life Science Advisors. Prior to founding Boston Life Science Advisors in 2009, Bob served as Chief Business Officer and Senior Vice President of Dynogen Pharmaceuticals, a clinical-stage drug development company focused on gastrointestinal and genitourinary disorders. From 1999 to 2002, Bob was Senior Vice President of Corporate Development for Boston Healthcare Associates, Inc., a management consulting firm in the life sciences industry. Bob previously was Vice President of Corporate Development for UroMed Corporation, and held several legal and general management positions with Bausch & Lomb. Bob holds a B.S. in Economics from the College of the Holy Cross, a J.D. from Syracuse University College of Law, and a Masters in Public Administration from the Maxwell School of Syracuse University.
Dr. Michael Spellman
Head of Preclinical Development
Dr. Michael Spellman is Head of Preclinical Development of Hunterian Medicine. He has over thirty years of drug development experience and has been an independent consultant since 2008. Dr. Spellman served as Senior Vice President of Pharmaceutical Development at Dynogen Pharmaceuticals from 2002 to 2008. He was previously Vice President of Quality and Vice President of Process Development at Millennium Pharmaceuticals, and Vice President of Preclinical Development at Coulter Pharmaceuticals. From 1984 to 1998, Dr. Spellman was employed at Genentech, where he led groups in analytical development and product characterization and then served as Director of Pharmacokinetics and Metabolism. Dr. Spellman received his bachelor’s degree from Assumption College and his Ph.D. in Biochemistry from Michigan State University, and performed postdoctoral research in the Department of Organic Chemistry at Stockholm University.
James Silverglad serves as Hunterian's general counsel. James began his legal career at Sullivan & Cromwell LLP in 2001, working in S&C’s world-leading mergers and acquisitions and financial institutions practices. From 2005-2010, he lead investment fund industry transactions, including seed investments, joint ventures, lending and private placements, in the Financial Services Group of Katten Muchin Rosenman LLP. In 2011-2012, James served as Associate General Counsel of CLS Bank International, the world’s largest multi-currency FX settlement system, and most recently served as legal counsel for Western Union in its Washington, DC office. James holds a J.D. from Columbia University School of Law, an LL.M in Taxation from Georgetown University Law Center, and a B.A. in Politics and Philosophy from New York University.